Great question, and the answer is nuanced. Let me break down the regulatory framework: USP <797> (2023 revision) sets default BUDs for sterile preparations based on compounding conditions: | Category | Storage Temp | Default BUD | |---|---|---| | Category 1 (basic) | Controlled room temp | 12 hours | | Category 1 (basic) | Refrigerated | 24 hours | | Category 2 (more controlled) | Controlled room temp | 4 days | | Category 2 (more controlled) | Refrigerated | 10 days | To assign BUDs BEYOND these defaults, the pharmacy MUST conduct or reference: 1. Sterility testing (USP <71>) 2. Endotoxin testing (USP <85>) 3. Stability-indicating assay (potency over time) 4. Container closure integrity testing So when you see a 503B facility assigning a 90-day or 180-day BUD, they should have stability data supporting that claim. Legitimate 503B facilities will have conducted formal stability studies: potency testing at time points (T=0, 30, 60, 90 days etc.), sterility testing at each time point, and particulate testing. If a 503A pharmacy is assigning a 90-day BUD, I'd ask them point-blank: "Do you have stability data supporting this beyond-use date?" If the answer is anything other than "yes, here's our stability protocol," be skeptical.

I run a contract stability testing laboratory. Here's what we typically see with compounded semaglutide preparations: Semaglutide base (lyophilized powder): - Very stable when stored properly - Can maintain potency for 12+ months at 2-8°C in sealed vials - The powder form is far more stable than the reconstituted solution Semaglutide solution (reconstituted or compounded as liquid): - Stability varies SIGNIFICANTLY based on: - pH: Optimal stability at pH 7.0-7.4 - Buffer system: Phosphate buffers tend to outperform others - Preservative: BAC (benzalkonium chloride) or phenol can interact with peptide; carboxymethylcellulose formulations vary - Concentration: Higher concentrations (5mg/mL+) may show more aggregation - Container: Glass vials outperform plastic for peptide stability - Storage temp: Refrigerated (2-8°C) dramatically extends stability vs. room temp Typical stability results we see: - At 2-8°C in glass vials with appropriate buffer: 90-120 days with >95% potency is achievable - At 25°C: 30-45 days before potency drops below 90% - With preservative (for multi-dose vials): antimicrobial effectiveness testing needed per USP <51> The BUD should be the SHORTER of: chemical stability data OR sterility assurance data. A vial can maintain potency for 120 days but if the sterility testing only supports 60 days, the BUD should be 60 days.

This is incredibly detailed, thank you. So the bottom line is: a 60-day BUD on a properly tested product stored refrigerated is totally reasonable and probably conservative? And the 180-day BUDs I've seen are... suspicious?

A 60-day BUD at 2-8°C for a well-formulated semaglutide solution is very reasonable and supported by typical stability data. 180 days is not impossible, but I'd want to see the data. Specifically: - Stability study with time points at 0, 30, 60, 90, 120, 150, and 180 days - Potency >90% at all time points - No significant increase in degradation products - Sterility maintained (no growth at all time points) - Endotoxin levels within limits - Particulate testing within USP <788> limits The challenge is that many compounders are assigning extended BUDs based on: - Published literature on the branded product (not directly applicable to their formulation) - API supplier stability data (for the raw material, not the finished preparation) - "Professional judgment" without supporting data All of these are problematic from a regulatory standpoint. USP <797> is clear: extended BUDs require preparation-specific stability data. My practical advice: use your vial within the labeled BUD, keep it refrigerated, and if you can't use it all within the BUD window, ask your compounder about smaller vial sizes or higher concentrations.